AUPH
Aurinia Pharmaceuticals Inc
NASDAQ · Biotechnology
$14.44
+0.18 (+1.26%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 212.05M | 122.74M | 596.78M | 554.79M | 498.94M |
| Net Income | 5.18M | 2.70M | -161,211,616 | -143,878,553 | -118,778,272 |
| EPS | — | — | — | — | — |
| Profit Margin | 2.5% | 2.3% | -27.0% | -25.9% | -23.8% |
| Rev Growth | +72.8% | +72.8% | +3.8% | +6.7% | +8.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 153.53M | 153.53M | 668.51M | 609.82M | 763.05M |
| Total Equity | 798.36M | 798.36M | 1.28B | 1.36B | 1.29B |
| D/E Ratio | 0.19 | 0.19 | 0.52 | 0.45 | 0.59 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 13.30M | 7.32M | -198,130,665 | -183,212,536 | -145,145,703 |
| Free Cash Flow | — | — | -93,265,267 | -112,933,113 | -81,032,986 |